Clinical neuropathology practice guide 5-2013: Markers of neuronal maturation

Clinical Neuropathology

Volumn 32, Issue 5, 2013, Pages 340-369

  Sarnat, Harvey B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acridine orange; Calbindin; Calretinin; Cellular maturation; Chromogranins; Enolases; Luxol fast blue; Microtubule associated proteins; Mitochondrial enzyme histochemistry; NeuN; Neuroblast; Neuronal markers; Silver impregnations; Synaptophysin

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINESTERASE; ALPHA INTERNEXIN; ALPHA SYNUCLEIN; BETA TUBULIN; BIOLOGICAL MARKER; CALBINDIN; CALCIUM BINDING PROTEIN; CALMODULIN; CALRETININ; CHOLINE ACETYLTRANSFERASE; CHROMOGRANIN A; CHROMOGRANIN B; DOUBLECORTIN; GLYCOGEN SYNTHASE KINASE 3; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROGENIN 2; NEUROMODULIN; NEURON SPECIFIC ENOLASE; NEURON SPECIFIC NUCLEAR PROTEIN; NUCLEIC ACID; PARVALBUMIN; PROTEIN S 100; SECRETOGRANIN II; SYNAPTOBREVIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNAPTOTAGMIN; TAU PROTEIN; VIMENTIN;

ALEXANDER DISEASE; ARTICLE; BRAIN DAMAGE; BRAIN MALFORMATION; BRAIN NERVE CELL; CELL MATURATION; CEREBROSPINAL FLUID; CORTICAL DYSPLASIA; DENDRITE; HUMAN; IMMUNOCYTOCHEMISTRY; INBORN ERROR OF METABOLISM; MULTIPLE CANCER; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PURKINJE CELL; SPINAL MUSCULAR ATROPHY; TAUOPATHY; TUBEROUS SCLEROSIS;

BIOLOGICAL MARKERS; BRAIN; CELL LINEAGE; HUMANS; NEUROGENESIS; NEURONS;

EID: 84884656209     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300638     Document Type: Article

References (235)

1. Schmechel DE, Brightman MW, Marangos PJ. Neurons switch from non-neuronal enolase to neuron-specific enolase during differentiation. Brain Res. 1980; 190: 195-214.
2. Sarnat HB. Vimentin immunohistochemistry in human fetal brain: methods of standard incubation versus thermal intensification achieve different objectives. Pediatr Dev Pathol. 1998; 1: 222-229.
3. Sarnat HB. Regional differentiation of the human fetal ependyma: immunocytochemical markers. J Neuropathol Exp Neurol. 1992; 51: 58-75.
4. Magavi SS, Macklis JD. Immunocytochemical analysis of neuronal differentiation. Methods Mol Biol. 2008; 438: 345-352.
5. Müllen RJ, Buck CR, Smith AM. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 1992; 116: 201-211.
6. Wolf HK, Buslei R, Schmidt-Kastner R, Schmidt-Kastner PK, Pietsch T, Wiestler OD, Blümcke I, Blümcke I. NeuN: a useful neuronal marker for diagnostic histopathology. J Histochem Cytochem. 1996; 44: 1167-1171.
7. Sarnat HB, Nochlin D, Born DE. Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in early human fetal nervous system. Brain Dev. 1998; 20: 88-94.
8. Kim KK, Adelstein RS, Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem. 2009; 284: 31052-31061.
9. Dent MA, Segura-Anaya E, Alva-Medina J, Aranda-Anzaldo A. NeuN/Fox-3 is an intrinsic component of the neuronal nuclear matrix. FEBS Lett. 2010; 584: 2767-2771.
10. Weyer A, Schilling K. Developmental and cell typespecific expression of the neuronal marker NeuN in the murine cerebellum. J Neurosci Res. 2003; 73: 400-409.
11. Schoenherr CJ, Anderson DJ. Silencing is golden: negative regulation in the control of neuronal gene transcription. Curr Opin Neurobiol. 1995; 5: 566-571.
12. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995; 267: 1360-1363.
13. Ernsberger U. Regulation of gene expression during early neuronal differentiation: evidence for patterns conserved across neuron populations and vertebrate classes. Cell Tissue Res. 2012; 348: 1-27.
14. Schuurmans C, Armant O, Nieto M, Stenman JM, Britz O, Klenin N, Brown C, Langevin LM, Seibt J, Tang H, Cunningham JM, Dyck R, Walsh C, Campbell K, Polleux F, Guillemot F. Sequential phases of cortical specification involve Neurogenin-dependent and -independent pathways. EMBO J. 2004; 23: 2892-2902.
15. Hand R, Bortone D, Mattar P, Nguyen L, Heng JI-T, Guerrier S, Boutt E, Peters E, Barnes AP, Parras C, Schuurmans C, Guillemot F, Polleux F. Phosphorylation of Neurogenin2 specifies the migration properties and the dendritic morphology of pyramidal neurons in the neocortex. Neuron. 2005; 48: 45-62.
16. Li S, Mattar P, Zinyk D, Singh K, Chaturvedi C-P, Kovach C, Dixit R, Kurrasch DM, Ma Y-C, Chan JA, Wallace V, Dilworth FJ, Brand M, Schuurmans C. GSK3 temporally regulates neurogenin 2 proneural activity in the neocortex. J Neurosci. 2012; 32: 7791-7805.
17. Han CW, Min BW, Kim Y, Jeong EH, Park CS, Woo YJ, Kim HS, Lee MC. Immunohistochemical analysis of developmental neural antigen expression in the balloon cells of focal cortical dysplasia. J Clin Neurosci. 2011; 18: 114-118.
18. Kumar SS, Buckmaster PS. Neuron-specific nuclear antigen NeuN is not detectable in gerbil subtantia nigra pars reticulata. Brain Res. 2007; 1142: 54-60.
19. Cannon JR, Greenamyre JT. NeuN is not a reliable marker of dopamine neurons in rat substantia nigra. Neurosci Lett. 2009; 464: 14-17.
20. Gill SK, Ishak M, Rylett RJ. Exposure of nuclear antigens in formalin-fixed, paraffin-embedded necropsy human spinal cord tissue: detection of NeuN. J Neurosci Methods. 2005; 148: 26-35.
21. Korzhevskii DE, Gilerovich EG, Zin'kova NN, Grigor'ev IP, Otellin VA. Immunocytochemical detection of brain neurons using the selective marker NeuN. Neurosci Behav Physiol. 2006; 36: 857-859.
22. Yang S, Donner LR. Detection of ganglion cells in the colonic plexuses by immunostaining for neuron-specific marker NeuN: an aid for the diagnosis of Hirschsprung disease. Appl Immunohistochem Mol Morphol. 2002; 10: 218-220.
23. Chung Y-N, Lee D-H, Yang H-J, Kim S-K, Lee Y-J, Lee M-S, Cho B-K, Kim D-H. Wang K-C. Expression of neuronal markers in the secondary neurulation of the chick embryo. Childs Nerv Syst. 2008; 24: 106-110.
24. Unal-Cevik I, Kilinç M, Gürsoy-Ozdemir Y, Gurer G, Dalkara T. Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res. 2004; 1015: 169-174.
25. Lee SH, Kim YJ, Lee KM, Ryu S, Yoon BW. Ischemic preconditioning enhances neurogenesis in the subventricular zone. Neuroscience. 2007; 146: 1020-1031.
26. Jahn R, Schiebler W, Ouimet C, Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA. 1985; 82: 4137-4141.
27. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. 1985; 41: 1017-1028.
28. Sarnat HB, Born DE. Synaptophysin immunocytochemistry with thermal intensification: a marker of terminal axonal maturation in the human fetal nervous system. Brain Dev. 1999; 21: 41-50.
29. Gincel D, Shoshan-Barmatz V. The synaptic vesicle protein synapatophysin: purification and characgterization of its channel activity. Biophys J. 2003; 83: 3223-3229.
30. Linstedt AD, Kelly R. B. Endocytosis of the synapatic vesicle protein, synaptophysin, requires the COOH-terminal tail. J Physiol. 1991; 85: 90-96.
31. Sarnat HB, Flores-Sarnat L, Trevenen CL. Synaptophysin immunoreactivity in the human hippocampus and neocortex from 6 to 41 weeks of gestation. J Neuropathol Exp Neurol. 2010; 69: 234-245.
32. Ulfig N, Setzer M, Neudörfer F, Saretzki U. Changing distribution patterns of synaptophysinimmunoreactive structures in the human dorsal striatum of the fetal brain. Anat Rec. 2000; 258: 198-209.
33. Sarnat HB, Auer RN, Flores-Sarnat L. Synaptogenesis in the fetal corpus striatum, globus pallidus, and substantia nigra: correlations with striosomes of Graybiel and dyskinesias in premature infants. J Child Neurol. 2013; 28: 60-69.
34. Sarnat HB, Flores-Sarnat L, Auer RN. N. Sequence of synaptogenesis in the human fetal and neonatal cerebellar system. Part 1. Guillain-Mollaret triangle (dentate-rubro-olivary-cerebellar circuit. Dev Neurosci. 2013; 35: 69-81.
35. Sarnat HB, Flores-Sarnat L, Auer R. N. Sequence of synaptogenesis in the human fetal and neonatal cerebellar system. Part 2. Pontine nuclei and cerebellar cortex. Dev Neurosci. 2013. ePub ahead of print: DOI: 10.1159/000351031, 28 March 2013.
36. Ulfig N, Chan WY. Expression of AKAP79 and synaptophysin in the developing human red nucleus. Neurosignals. 2002; 11: 95-102.
37. Masliah E, Terry RD, Alford M, DeTeresa R. Quantitative immunohistochemistry of synaptophysin in human neocortex: an alternative method to estimate density of presynaptic terminals in paraffin sections. J Histochem Cytochem. 1990; 38: 837-844.
38. Cheng D, Hoogenraad CC, Rush J, Ramm E, Schlager MA, Duong DM, Xu P, Wijayawardana SR, Hanfelt J, Nakagawa T, Sheng M, Peng J. Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol Cell Proteomics. 2006; 5: 1158-1170.
39. Lendvai D, Morawski M, Négyessy L, Gáti G, Jäger C, Baksa G, Glasz T, Attems J, Tanila H, Arendt T, Harkany T, Alpár A. Neurochemical mapping of the human hippocampus reveals perisynaptic matrix around functional synapses in Alzheimer's disease. Acta Neuropathol. 2013; 125: 215-229.
40. Hamdan FF, Daoud H, Piton A, Gauthier J, Dobrzeniecka S, Krebs MO, Joober R, Lacaille JC, Nadeau A, Milunsky JM, Wang Z, Carmant L, Mottron L, Beauchamp MH, Rouleau GA, Michaud JL. De novo SYNGAP1 mutations in nonsyndromic intellectual disability and autism. Biol Psychiatry. 2011; 69: 898-901.
41. Vazquez LE, Chen HJ, Sokolova I, Knuesel I, Kennedy MB. SynGAP regulates spine formation. J Neurosci. 2004; 24: 8862-8872.
42. Clement JP, Aceti M, Creson TK, Ozkan ED, Shi Y, Reish NJ, Almonte AG, Miller BH, Wiltgen BJ, Miller CA, Xu X, Rumbaugh G. Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell. 2012; 151: 709-723.
43. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ. Tau and a-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007; 62: 145-153.
44. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncoso JC. Alphasynuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. 2005; 64: 156-162.
45. Beyer K, Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neuropathol Exp Neurol. 2007; 66: 965-974.
46. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of a-synuclein fibrils through axonal transport. Ann Neurol. 2012; 72: 517-524.
47. Taschenberger G, Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, Kügler S. Aggregation of a-Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 2012; 123: 671-683.
48. Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of a-synucleinopathies: emerging concepts. Acta Neuropathol. 2011; 121: 675-693.
49. Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Morris J et al; Brain-Net Europe Consortium. Assessment of a-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2008; 67: 125-143.
50. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH. Evaluation of a-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008; 116: 277-288.
51. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, Leisser I, Verchère J, Baron T, Alafuzoff I, Budka H, Perret-Liaudet A, Lachmann I. An antibody with high reactivity for disease-associated a-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012; 124: 37-50.
52. Petersen K, Olesen OF, Mikkelsen JD. Developmental expression of a-synuclein in rat hippocampus and cerebral cortex. Neuroscience. 1999; 91: 651-659.
53. Raghavan R, Kruijff L, Sterrenburg MD, Rogers BB, Hladik CL, White CL III. Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol. 2004; 7: 506-516.
54. Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol. 1984; 115: 458-468.
55. Nolan JA, Trojanowski JQ, Hogue-Angeletti R. Neurons and neuroendocrine cells contain chromogranin: detection of the molecule in normal bovine tissues by immunochemical and immunohistochemical methods. J Histochem Cytochem. 1985; 33: 791-798.
56. Varndell IM, Lloyd RV, Wilson BS, Polak JM. Ultrastructural localization of chromogranin: a potential marker for the electron microscopical recognition of endocrine cell secretory granules. Histochem J. 1985; 17: 981-992.
57. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986; 314: 1145-1151.
58. Lloyd RV. Immunocytochemical localization of catecholamines, catecholamine synthesizing enzymes, and chromogranins in neuroendocrine cells and tumors. In: Advances in Immunohisotochemistry. DeLellis RA, ed. NY: Raven Press. 1988. p. 317-339.
59. Gratzl M. Distribution of the Ca++ binding protein chromogranin A in the pancreatic islets. Exp Brain Res. 1987; 16: 130-133.
60. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT. Structure and function of the chromogranin A gene. Clues to evolution and tissuespecific expression. J Biol Chem. 1991; 266: 13130-13134.
61. Muñoz DG. Monodendritic neurons: a cell type in the human cerebellar cortex identified by chromogranin A-like immunoreactivity. Brain Res. 1990; 528: 336-338.
62. Muñoz DG, Kobylinski L, Henry DD, George DH. Chromogranin A-like immunoreactivity in the human brain: distribution in bulbar medulla and cerebral cortex. Neuroscience. 1990; 34: 533-543.
63. Erickson JD, Lloyd R, Trojanowski JQ, Iacangelo A, Eiden E. Sites of synthesis of chromogranins A and B in the human brain. Neuropeptides. 1992; 21: 239-244.
64. Reiffen FU, Gratzl M. Chromogranins, widespread in endocrine and nervous tissue, bind Ca2+. FEBS Lett. 1986; 195: 327-330.
65. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J. 1965; 97: 40C-41C.
66. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of chromaffin protein, chromogranin, from the adrenal medulla after splanchnic nerve stimulation. Nature. 1967; 215: 58-59.
67. Winkler H, Apps DK, Fischer-Colbrie R. The molecular function of adrenal chromaffin granules: established facts and unresolved topics. Neuroscience. 1986; 18: 261-290.
68. Gibson CJ, Muñoz DG. Chromogranin A inhibits retinal dopamine release. Brain Res. 1993; 622: 303-306.
69. Shen Z, Larsson LT, Malmfors G, Oberg K, Eriksson B, Sundler F. Chromogranin A and B in neuronal elements in Hirschsprung's disease: an immunocytochemical and radioimmunoassay study. J Pediatr Surg. 1994; 29: 1293-1301.
70. Portela-Gomes GM, Stridsberg M, Johansson H, Grimelius L. Co-localization of synaptophysin with different neuroendocrine hormones in the human gastrointestinal tract. Histochem Cell Biol. 1999; 111: 49-54.
71. Giovanella L, La Rosa S, Ceriani L, Uccella S, Erba P, Garancini S. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers. 1999; 14: 160-166.
72. Militello C, Cannizzaro R, Pradella P, Volpin E, Spirch S, Buonadonna A, De Appollonia L, Rossi C, Sigon R, Cipresso S, Terranova O. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia]. Chir Ital. 1999; 51: 45-51. in Italian
73. Bock E, Dissing J. Demonstration of enolase activity connected to the brain-specific protein 14-3-2. Scand J Immunol. 1975; 4 (Suppl): 31-36.
74. Marangos PJ, Zis AP, Clark RL, Goodwin FK. Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons. Brain Res. 1978; 150: 117-133.
75. Schmechel DE, Marangos PJ, Zis AP, Brightman M, Goodwin FK. Brain endolases as specific markers of neuronal and glial cells. Science. 1978; 199: 313-315.
76. Marangos PJ, Parma AM, Goodwin FK. Functional properties of neuronal and glial isoenzymes of brain enolase. J Neurochem. 1978; 31: 727-732.
77. Ghandour MS, Langley OK, Keller A. A comparative imunohistological study of cerebellar enolases. Double labelling technique and immunoelectronmicroscopy. Exp Brain Res. 1981; 41: 271-279.
78. Royds JA, Parsons MA, Taylor CB, Timperley WR. Enolase isoenzyme distribution in the human brain and its tumours. J Pathol. 1982; 137: 37-49.
79. Marangos PJ, Schmechel DE, Parma AM, Goodwin FK. Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res. 1980; 190: 185-193.
80. Langley OK, Ghandour MS. An immunocytochemical investigation of non-neuronal enolase in cerebellum: a new astrocyte marker. Histochem J. 1981; 13: 137-148.
81. Friedlander RM, Gagliardini V, Rotello RJ, Yuan J. Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis. J Exp Med. 1996; 184: 717-724.
82. Royds JA, Davies-Jones GA, Lewtas NA, Timperley WR, Taylor CB. Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. J Neurol Neurosurg Psychiatry. 1983; 46: 1031-1036.
83. Steinberg R, Gueniau C, Scarna H, Keller A, Worcel M, Pujol JF. Experimental brain ischemia: neuron-specific enolase level in cerebrospinal fluid as an index of neuronal damage. J Neurochem. 1984; 43: 19-24.
84. Tekgul H, Yalaz M, Kutukculer N, Ozbek S, Kose T, Akisu M, Kultursay N, Gokben S. Value of biochemical markers for outcome in term infants with asphyxia. Pediatr Neurol. 2004; 31: 326-332.
85. Suzuki Y, Mogami Y, Toribe Y, Yamada K, Yanagihara K, Hirata I, Mano T. Prolonged elevation of serum neuron-specific enolase in children after clinical diagnosis of brain death. J Child Neurol. 2012; 27: 7-10.
86. Karkela J, Bock E, Kaukinen S. CSF neuron specific enolase as a quantitative marker of neuronal damage. J Neurochem. 1993; 116: 100-109.
87. van den Doel EMH, Rijksen G, Staal GE. Intérêt et limites de l'étude de la gamma-énolase dans le liquide céphalo-rachidien comme témoin de la dégradation neuronale. Rev Neurol (Paris). 1988; 144: 452-455.
88. DeGiorgio CM, Heck CN, Rabinowicz AL, Gott PS, Smith T, Correale J. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999; 52: 746-749.
89. DeGiorgio CM, Gott PS, Rabinowicz AL, Heck CN, Smith TD, Correale JD. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia. 1996; 37: 606-609.
90. Büttner T, Lack B, Jäger M, Wünsche W, Kühn W, Müller T, Przuntek H, Postert T. Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. J Neurol. 1999; 246: 459-461.
91. Steinhoff BJ, Tumani H, Otto M, Mursch K, Wiltfang J, Herrendorf G, Bittermann HJ, Felgenhauer K, Paulus W, Markakis E. Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res. 1999; 36: 75-82.
92. O'Regan ME, Brown JK. Serum neuron specific enolase: a marker for neuronal dysfunction in children with continuous EEG epileptiform activity. Eur J Paediatr Neurol. 1998; 2: 193-197.
93. Hamad SA, Eltayeb AA, Ahmad HK, Abdou MA. Brain function in children with uncomplicated epilepsy: relationship to biomarkers of brain damage (neuron-specific enolase and S100ß protein). J Pediatr Epilepsy. 2013. in press.
94. Woertgen C, Albert R, Köhler M, Rzepecki A, Rothoerl RD, Bein T, Brawanski A. Ventricular tapping seems to have no influence on S-100B and NSE serum concentrations. Neurosurg Rev. 2004; 27: 178-180.
95. Rodríguez-Núñez A, Cid E, Eirís J, Rodríguez-García J, Camiña F, Rodríguez-Segade S, Castro-Gago M. Neuron-specific enolase levels in the cerebrospinal fluid of neurologically healthy children. Brain Dev. 1999; 21: 16-19.
96. Watanabe M, Sakimura K, Takahashi Y, Kondo H. Ontogenic changes in expression of neuron-specific enolase (NSE) and its mRNA in the Purkinje cells of the rat cerebellum: immunohistochemical and in situ hybridization study. Brain Res Dev Brain Res. 1990; 53: 89-96.
97. Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978; 276: 834-836.
98. Nishimura M, Takashima S, Takeshita K, Tanaka J. Developmental changes of neuron-specific enolase in human brain: an immunohistochemical study. Brain Dev. 1985; 7: 1-6.
99. Hamre KM, Cassell MD, West JR. The development of laminar staining for neuron-specific enolase in the rat somatosensory cortex. Brain Res Dev Brain Res. 1989; 46: 213-220.
100. De Camilli P, Miller PE, Navone F, Theurkauf WE, Vallee R. B. Distribution of microtubule-associated protein 2 in the nervous system of the rat studied by immunofluorescence. Neuroscience. 1984; 11: 819-846.
101. Schoenfeld TA, McKerracher L, Obar R, Vallee RB. MAP 1A and MAP 1B are structurally related microtubule associated proteins with distinct developmental patterns in the CNS. J Neurosci. 1989; 9: 1712-1730.
102. Johnson GVW, Jope RS. The role of microtubuleassociated protein 2 (MAP2) in neuronal growth, plasticity and degeneration. J Neurosci Res. 1992; 117: 80-86.
103. Ulfig N. Ganglionic eminence of the human fetal brain-new vistas. Anat Rec. 2002; 267: 191-195.
104. Riederer BM, Draberova E, Viklicky V, Draber P. Changes of MAP2 phosphorylation during brain development. J Histochem Cytochem. 1995; 43: 1269-1284.
105. Janke C, Kneussel M. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci. 2010; 33: 362-372.
106. Matus A. Stiff microtubules and neuronal morphology. Trends Neurosci. 1994; 17: 19-22.
107. Cosenza MA, Zhao ML, Shankar SL, Shafit-Zagardo B, Lee SC. Up-regulation of MAP2e-expressing oligodendrocytes in the white matter of patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol. 2002; 28: 480-488.
108. Giovanini MA, Reier PJ, Eskin TA, Anderson DK. MAP2 expression in the developing human fetal spinal cord and following xenotransplantation. Cell Transplant. 1997; 6: 339-346.
109. Honig LS, Herrmann K, Shatz CJ. Developmental changes revealed by immunohistochemical markers in human cerebral cortex. Cereb Cortex. 1996; 6: 794-806.
110. Chun JJM, Shatz CJ. The earliest-generated neurons of the cat cerebral cortex: characterization by MAP2 and neurotransmitter immunohistochemistry during fetal life. J Neurosci. 1989; 9: 1648-1667.
111. Ulfig N, Feldhaus C, Setzer M, Bohl J. Expression of MAP1a and MAP1b in the ganglionic eminence and the internal capsule of the human fetal brain. Neurosci Res. 2000; 38: 397-405.
112. Forleo P, Couchie D, Chabas S, Nunez J. Four repeat high-mol-wt MAP2 forms in rat dorsal root ganglia. J Mol Neurosci. 1996; 7: 193-201.
113. Ávila J, Domínguez J, Díaz-Nido J. Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol. 1994; 38: 13-25.
114. Ohyu J, Yamanouchi H, Takashima S. Immunohistochemical study of microtubule-associated protein 5 (MAP5) expression in the developing human brain. Brain Dev. 1997; 19: 541-546.
115. Katsetos CD, Frankfurter A, Christakos S, Mancall EL, Vlachos IN, Urich H. Differential localization of class III, ß-tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol. 1993; 52: 655-666.
116. Dráberová E, Del Valle L, Gordon J, Marková V, Šmejkalová B, Bertrand L, de Chadarévian J-P, Agamanolis DP, Legido A, Khalili K, Dráber P, Katsetos CD, Smejkalová B, Bertrand L, de Chadarévian J-P, Agamanolis DP, Legido A, Khalili K, Dráber P, Katsetos CD. Class III ß-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J Neuropathol Exp Neurol. 2008; 67: 3341-3354.
117. Fanarraga ML, Avila J, Zabala JC. Expression of unphosphorylated class III beta-tubulin isotype in neuroepithelial cells demonstrates neuroblast commitment and differentiation. Eur J Neurosci. 1999; 11: 516-527.
118. Sugita Y, Nakamura Y, Yamamoto M, Oda E, Tokunaga O, Shigemori M. Expression of tubulin beta II in neuroepithelial tumors: reflection of architectural changes in the developing human brain. Acta Neuropathol. 2005; 110: 127-134.
119. Katsetos CD, Karkavelas G, Herman MM, Vinores SA, Provencio J, Spano AJ, Frankfurter A. Class III beta-tubulin isotype (beta III) in the adrenal medulla: I. Localization in the developing human adrenal medulla. Anat Rec. 1998; 250: 335-343.
120. Korzhevskii DE, Petrova ES, Kirik OV, Otellin VA. Assessment of neuron differentiation during embryogenesis in rats using immunocytochemical detection of doublecortin. Neurosci Behav Physiol. 2009; 39: 513-516.
121. Francis F, Koulakoff A, Boucher D, Chafey P, Schaar B, Vinet MC, Friocourt G, McDonnell N, Reiner O, Kahn A, McConnell SK, Berwald-Netter Y, Denoulet P, Chelly J. Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuron. 1999; 23: 247-256.
122. Fu X, Brown KJ, Yap CC, Winckler B, Jaiswal JK, Liu JS. Doublecortin (Dcx) family proteins regulate filamentous actin structure in developing neurons. J Neurosci. 2013; 33: 709-721.
123. Jean DC, Baas PW, Black MM. A novel role for doublecortin and doublecortin-like kinase in regulating growth cone microtubules. Hum Mol Genet. 2012; 21: 5511-5527.
124. Spampanato J, Sullivan RK, Turpin FR, Bartlett PF, Sah P. Properties of doublecortin-expressing neurons in the adult mouse dentate gyrus. PLoS One. 2012; 7: e41029.
125. Filipovic R, Santhosh Kumar S, Fiondella C, Loturco J. Increasing doublecortin expression promotes migration of human embryonic stem cellderived neurons. Stem Cells. 2012; 30: 1852-1862.
126. Yap CC, Vakulenko M, Kruszek K, Motamedi B, Digilio L, Liu JS, Winckler B. Doublecortin (DCX) mediates endocytosis of neurofascin independently of microtubule binding. J Neurosci. 2012; 32: 7493-7453.
127. Marcorelles P, Laquerrière A, Adde-Michel C, Marret S, Saugier-Veber P, Beldjord C, Friocourt G. Evidence for tangential migration disturbances in human lissencephaly resulting from a defect in LIS1, DCX and ARX genes. Acta Neuropathol. 2010; 120: 503-515.
128. Ávila J, de Barreda EG, Fuster-Matanzo A, Simón D, Llorens-Martín M, Engel T, Lucas JJ, Díaz-Hernández M, Hernández F. Looking for novel functions of tau. Biochem Soc Trans. 2012; 40: 653-655.
129. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010; 67: 953-966.
130. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM-Y, Trojanowski JQ. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain. 2012; 135: 807-818.
131. Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, Arevalo JB, Heinsen H, Huang EJ, Rosen H, Miller BL, Gan L, Seeley WW. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013; 125: 581-593.
132. Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2010; 29: 271-288.
133. Mackenzie I, Neumann M, Cairns NJ, Muñoz DG, Isaacs A. M. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43. J Mol Neurosci. 2012; 122: 87-89.
134. Sen A, Thom M, Martinian L, Harding B, Cross JH, Nikolic M, Sisodiya SM. Pathological tau tangles localize to focal cortical dysplasia in older patients. Epilepsia. 2007; 48: 1447-1454.
135. Aronica E, Becker AJ, Spreafico R. Malformations of cortical development. Brain Pathol. 2012; 22: 380-401.
136. Yamanouchi H, Zhang W, Jay V, Becker LE. Enhanced expression of microtubule-associated protein 2 in large neurons of cortical dysplasia. Ann Neurol. 1996; 39: 57-61.
137. Tsai V, Parker WE, Orlova KA, Baybis M, Chi AWS, Berg B, Birnbaum J, Estevez J, Sarnat HB, Flores-Sarnat L, Aronica E, Crino PB. Fetal mTOR pathway activation in tuberous sclerosis complex. Cereb Cortex. 2012; e-pub ahead of print, 18 October 2012. 10.1093/cercor/bhs310.
138. Sarnat HB, Flores-Sarnat L, Crino P, Hader W, Bello-Espinosa L. Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol. 2012; 50: 330-345.
139. Dickey CA, Koren J, Zhang Y-J, Xu Y-F, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci USA. 2008; 105: 3622-3627.
140. Richter-Landsberg C. The oligodendroglia cytoskeleton in health and disease. J Neurosci Res. 2000; 59: 11-18.
141. Shafit-Zagarado B, Rockwood J, Davies P, Kress Y, Lee S. C. MAP-2+13, a novel microtubule-associated protein expressed early in human oligodendrocyte maturation. Glia. 2000; 29: 233-245.
142. Kaneda M, Nagashima M, Mawatari K, Nunome T, Muramoto K, Sugitani K, Kato S. Growth-associated protein43 (GAP43) is a biochemical marker for the whole period of fish optic nerve regeneration. Adv Exp Med Biol. 2010; 664: 97-104.
143. Yang Y, Tandon P, Liu Z, Sarkisian MR, Stafstrom CE, Holmes GL. Synaptic reorganization following kainic acid-induced seizures during development. Brain Res Dev Brain Res. 1998; 107: 169-177.
144. Yuan A, Sasaki T, Kumar A, Peterhoff CM, Rao MV, Liem RK, Julien JP, Nixon RA. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci. 2012; 32: 8501-8508.
145. Osborn M, Weber K. Intermediate filaments: celltype-specific markers in differentiation and pathology. Cell. 1982; 31: 303-306.
146. Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 1996; 19: 187-217.
147. Dale JM, García ML. Neurofilament phosphorylation during development and diseases: Which came first, the phosphorylation or the accumulation? J Amino Acids. 2012; 2012: 382107. 10.1155/2012/382107
148. Pundir AS, Hameed LS, Dikshit PC, Kumar P, Mohan S, Radotra B, Shankar SK, Mahadevan A, Iyengar S. Expression of medium and heavy chain neurofilaments in the developing human auditory cortex. Brain Struct Funct. 2012; 217: 303-321.
149. Kaplan MP, Chin SS, Fliegner KH, Liem RK. Alpha-internexin, a novel neuronal intermediate filament protein, precedes the low molecular weight neurofilament protein (NF-L) in the developing rat brain. J Neurosci. 1990; 10: 2735-2748.
150. Arnold SE, Trojanowski JQ. Human fetal hippocampal development: II. The neuronal cytoskeleton. J Comp Neurol. 1996; 367: 293-307.
151. Crino PB, Trojanowski JQ, Eberwine J. Internexin, MAP1B, and nestin in cortical dysplasia as markers of developmental maturity. Acta Neuropathol. 1997; 93: 619-627.
152. Ducray F, Crinière E, Idbaih A, Mokhtari K, Marie Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M. alpha-Internexin expression identifies 1p19q codeleted gliomas. Neurology. 2009; 72: 156-161.
153. Liu CH, Chien CL. Molecular cloning and charterization of chicken neuronal intermediate filament protein a-internexin. J Comp Neurol. 2013; 521: 2147-2164.
154. Gómez TM, Snow DM, Letourneau PC. Characterization of spontaneous calcium transients in nerve growth cones and their effect on growth cone migration. Neuron. 1995; 14: 1233-1246.
155. Kater SB, Mattson MP, Cohan C, Connor J. Calcium regulation of the neuronal growth cone. Trends Neurosci. 1988; 11: 315-321.
156. Frassoni C, Arcelli P, Selvaggio M, Spreafico R. Calretinin immunoreactivity in the developing thalamus of the rat: a marker of early generated thalamic cells. Neuroscience. 1998; 83: 1203-1214.
157. Gotzos V, Schwaller B, Hetzel N, Bustos-Castillo M, Celio MR. Expression of the calcium binding protein calretinin in WiDr cells and its correlation to their cell cycle. Exp Cell Res. 1992; 202: 292-302.
158. Rasmussen CD, Means A. R. Calmodulin, cell growth and gene expression. Trends Neurosci. 1992; 46: 433-438.
159. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 1994; 263: 1618-1623.
160. Varghese S, Lee S, Huang Y-C, Christakos S. Analysis of rat vitamin
161. Celio MR, Norman AW. Nucleus basalis Meynert neurons contain the vitamin D-induced calciumbinding protein (Calbindin-D 28k). Anat Embryol (Berl). 1985; 173: 143-148.
162. Heizmann CW, Braun K. Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. Trends Neurosci. 1992; 15: 259-264.
163. Baimbridge KG, Celio MR, Rogers JH. Calciumbinding proteins in the nervous system. Trends Neurosci. 1992; 15: 303-308.
164. Ulfig N. Calcium-binding proteins in the human developing brain. Adv Anat Embryol Cell Biol. 2002; 165: III-IX., 1-92.
165. Parmentier M, Lefort A. Structure of the human brain calcium-binding protein calretinin and its expression in bacteria. Eur J Biochem. 1991; 196: 79-85.
166. Du L, Poovaiah BW. Ca2+/calmodulin is critical for brassinosteroid biosynthesis and plant growth. Nature. 2005; 437: 741-745.
167. Ellis JH, Richards DE, Rogers JH. Calretinin and calbindin in the retina of the developing chick. Cell Tissue Res. 1991; 264: 197-208.
168. Pochet R, Parmentier M, Lawson DE, Pasteels JL. Rat brain synthesizes two 'vitamin D-dependent' calcium-binding proteins. Brain Res. 1985; 345: 251-256.
169. Ben-Ari Y. Basic developmental rules and their implications for epilepsy in the immature brain. Epileptic Disord. 2006; 8: 91-102.
170. Yu MC, Cho E, Luo CB, Li WWW, Shen WZ, Yew DT. Immunohistochemical studies of GABA and parvalbumin in the developing human cerebellum. Neuroscience. 1996; 70: 267-276.
171. Yew DT, Luo CB, Heizmann CW, Chan WY. Differential expression of calretinin, calbindin D28K and parvalbumin in the developing human cerebellum. Brain Res Dev Brain Res. 1997; 103: 37-45.
172. Ulfig N. Expression of calbindin and calretinin in the human ganglionic eminence. Pediatr Neurol. 2001; 24: 357-360.
173. Kim I-B, Park D-K, Oh S-J, Chun MH. Horizontal cells of the rat retina show choline acetyltransferase-and vesicular acetylcholine transporter-like immunoreactivities during early postnatal developmental stages. Neurosci Lett. 1998; 253: 83-86.
174. Enderlin S, Norman AW, Celio MR. Ontogeny of the calcium binding protein calbindin D-28k in the rat nervous system. Anat Embryol (Berl). 1987; 177: 15-28.
175. Fonseca M, Dél Río JA, Martínez A, Gómez S, Soriano E. Development of calretinin immunoreactivity in the neocortex of the rat. J Comp Neurol. 1995; 361: 177-192.
176. Liu FC, Graybiel AM. Transient calbindin-D28kpositive systems in the telencephalon: ganglionic eminence, developing striatum and cerebral cortex. J Neurosci. 1992; 12: 674-690.
177. Kostovic I, Rakic P. Developmental history of the transient subplate zone in the visual and somatosensory cortex of the macaque monkey and human brain. J Comp Neurol. 1990; 297: 441-470.
178. Kordower JH, Mufson EJ. Nerve growth factor receptor-immunoreactive neurons within the developing human cortex. J Comp Neurol. 1992; 323: 25-41.
179. Allendoerfer KL, Shatz CJ. The subplate, a transient neocortical structure: its role in the development of connections between thalamus and cortex. Annu Rev Neurosci. 1994; 17: 185-218.
180. Letinic K, Kostovic I. Transient patterns of calbindin-D28k expression in the developing striatum of man. Neurosci Lett. 1996; 220: 211-214.
181. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990; 13: 244-254.
182. Setzer M, Ulfig N. Differential expression of calbindin and calretinin in the human fetal amygdala. Microsc Res Tech. 1999; 46: 1-17.
183. Ulfig N, Rupp M, Braak E, Braak A. Hypothalamic tuberomamillary nucleus in man: nuclear configuration, cell types and parvalbumin-immunoreactive neurons. Eur J Neurosci. 1989; (Suppl 2): 216.
184. Jeon CJ, Pyun J-K, Yang HW. Calretinin and calbindin D28K immunoreactivity in the superficial layers of the rabbit superior colliculus. Neuroreport. 1998; 9: 3847-3852.
185. Zettel ML, Frisina RD, Haider SEA, O'Neill WE. Age-related changes in calbindin D-28k and calretinin immunoreactivity in the inferior colliculus of CBA/CaJ and C57Bl/6 mice. J Comp Neurol. 1997; 386: 92-110.
186. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995; 37: 417-429.
187. Elmahdy HS, Elmashad AE, Hagag AA, Hamouda S. Serum protein S100B and nucleated red blood cell counts as early markers of cerebral damage in neonates with hypoxic-ischemic encephalopathy. J Pediatr Neurol. 2009; 7: 337-343.
188. Schültke E, Sadanand V, Kelly ME, Griebel RW, Juurlink BH. Can admission S-100ß predict the extent of brain damage in head trauma patients? Can J Neurol Sci. 2009; 36: 612-616.
189. Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD. Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry. 1998; 65: 930-932.
190. Geramizadeh B, Hayati K, Rahsaz M, Hosseini SV. Assessing the interstitial cells of Cajal, cells of enteric nervous system and neurotransmitters in slow transit constipation, using immunohistochemistry for CD117, PGP9.5 and serotonin. Hepatogastroenterology. 2009; 56: 1670-1674.
191. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer. 2008; 123: 753-759.
192. Vento P, Soinila S. Quantitative comparison of growth-associated protein GAP-43, neuron-specific enolase, and protein gene product 9.5 as neuronal markers in mature human intestine. J Histochem Cytochem. 1999; 47: 1405-1416.
193. Klüver H, Barrera E. A method for the combined staining of cells and fibers in the nervous system. J Neuropathol Exp Neurol. 1953; 12: 400-403.
194. Dawson TP, Neal JW, Llewellyn L. Thomas C. Neuropathology Techniques. London, U.K.: Arnold. 2003. pp 164-176.
195. Yakovlev PI, Lecours A-R. The myelination cycles of regional maturation of the brain. In: Minkowsky A, editor. Regional Development of the Brain in Early Life. Philadelphia: FA Davis; 1967. p. 3-70.
196. Rorke LB, Riggs H. E. Myelination in the Brain of the Newborn. Philadelphia, Toronto: Lippincott; 1969.
197. Gilles F. H. Myelination in the human brain. Brain Pathol. 1976; 7: 244-248.
198. Pellerin L, Therianos S, Magistretti PJ. The metabolic functions of glial cells. In: Jessen KR, Richardson WM (eds). Glial Cell Development. 2nd ed. Oxford, UK: Oxford University Press; 2001. p. 91-107.
199. Hamprecht B, Verleysdonk S, Wiesinger H. Enzymes of carbohydrate and energy metabolism. In: Kettenmann H, Ransom BR (eds). Neuroglia, 2nd ed. Oxford UK, NY: Oxford University Press; 2005. p. 202-215.
200. Sarnat HB. L'acridine-orange: un fluorochrome des acides nucléiques pour l'étude des cellules musculaires et nerveuses. Rev Neurol (Paris). 1985; 141: 120-127.
201. Sarnat HB. Répartition de l'A.R.N. au cours de la migration neuronale dans les cerveaux normaux et dysplastiques en développement chez l'homme. Etude à l'acridine-orange. Rev Neurol (Paris). 1989; 145: 127-133.
202. Sarnat HB, Jacob P, Jiménez C. Atrophie spinale musculaire: l'évanouissement de la fluorescence à l'ARN des neurons moteurs en dégénerescence: une étude à l'acridine-orange. Rev Neurol (Paris). 1989; 145: 305-311.
203. Sarnat HB, Seagram GF, Trevenen CL, Rubin SZ. A fluorochromic stain for nucleic acids to demonstrate submucosal and myenteric neurons in Hirschsprung's disease. Am J Clin Pathol. 1985; 83: 722-725.
204. Sarnat HB, Flores-Sarnat L, Hader W, Bello-Espinosa L. Mitochondrial "hypermetabolic" neurons in paediatric epileptic foci. Can J Neurol Sci. 2011; 38: 909-917.
205. Conn HJ, Darrow MA, Emmel VM. Staining Procedures used by the Biological Stain Commission. Baltimore: Williams & Wilkins; 1960. p. 98-116.
206. Ramóny Cajal S. L'histologie du système nerveux de l'homme et des vértébrés. Paris: Masson 1909-1911. Reprinted in English translation, Histology of the Nervous System of Man and Vertebrates. (in 2 volumes). NY, Oxford: Oxford University Press; 1995.
207. Marín-Padilla M. The Human Brain. Prenatal Development and Structure. Heidelberg, London, NY: Springer-Verlag; 2011.
208. Nauta WJH. Silver impregnation of degenerating axons. In: Windle WF (ed). New Research Techniques of Neuroanatomy. Springfield, Illinois, USA: Chas. C. Thomas, Publisher; 1957. p. 17-26.
209. Sarnat HB, Flores-Sarnat L. Precocious and delayed neocortical synaptogenesis in fetal holoprosencephaly. Clin Neuropathol. 2013; 32: 255-268.CrossRef
210. Takei Y, Kondo SA, Harada A, Inomata S, Noda T, Hirokawa N. Delayed development of nervous system in mice homozygous for disrupted microtubule-associated protein 1B (MAP1B) gene. J Cell Biol. 1997; 137: 1615-1626.
211. Sarnat HB, Flores-Sarnat L. Radial microcolumnar cortical architecture: maturational arrest or cortical dysplasia? Pediatr Neurol. 2013; 48: 259-270.
212. Sarnat HB, Flores-Sarnat L, Pinter JD. Chapter 4. Neuroembryology. In: Youman's Neurological Surgery, 6th ed., Winn HR (ed). Philadelphia: Saunders-Elsevier. 2012; p. 78-97. Supplementary references e10-e14.
213. Rakic P. Guidance of neurons migrating to the fetal monkey neocortex. Brain Res. 1971; 33: 471-476.
214. Rakic P. Radial versus tangential migration of neuronal clones in the developing cerebral cortex. Proc Natl Acad Sci USA. 1995; 92: 11323-11327.
215. Sanes JR, Yamagata M. Formation of laminaspecific synaptic connections. Curr Opin Neurobiol. 1999; 9: 79-87.
216. Hevner RF. Layer-specific markers as probes for neuron type identity in human neocortex and malformations of cortical development. J Neuropathol Exp Neurol. 2007; 66: 101-109.
217. Sarnat HB, Flores-Sarnat L. Cajal-Retzius and subplate neurons: their role in cortical development. Eur J Paediatr Neurol. 2002; 6: 91-97.
218. Ben-Ari Y, Khalilov I, Represa A, Gozlan H. Interneurons set the tune of developing networks. Trends Neurosci. 2004; 27: 422-427.
219. Akerman CJ, Cline HT. Refining the roles of GABAergic signaling during neural circuit formation. Trends Neurosci. 2007; 30: 382-389.
220. Ulfig N, Szabo A, Bohl J. Effect of fetal hydrocephalus on the distribution patterns of calciumbinding proteins in the human occipital cortex. Pediatr Neurosurg. 2001; 34: 20-32.
221. Crino PB, Trojanowski JQ, Dichter MA, Eberwine J. Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. Proc Natl Acad Sci USA. 1996; 93: 14152-14157.
222. Crino PB. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol. 2013; 125: 317-332.
223. Flores-Sarnat L, Sarnat HB, Dávila-Gutiérrez G, Álvarez A. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol. 2003; 18: 776-785.
224. Blümcke I, Vinters HV, Armstrong D, Aronica E, Thom M, Spreafico R. Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord. 2009; 11: 181-193.
225. Abel TW, Baker SJ, Fraser MM, Tihan T, Nelson JS, Yachnis AT, Bouffard JP, Mena H, Burger PC, Eberhart CG. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol. 2005; 64: 341-349.
226. Valencia I, Legido A, Yelin K, Khurana D, Kothare SV, Katsetos CD. Anomalous inhibitory circuits in cortical tubers of human tuberous sclerosis complex associated with refractory epilepsy: aberrant expression of parvalbumin and calbindin-D28k in dysplastic cortex. J Child Neurol. 2006; 21: 1058-1063.
227. Barinka F, Druga R, Marusic P, Krsek P, Zamecnik J. Calretinin immunoreactivity in focal cortical dysplasias and in non-malformed epileptic cortex. Epilepsy Res. 2010; 88: 76-86.
228. Sloviter RS, Sollas AL, Barbaro NM, Laxer KD. Calcium-binding protein (calbindin-D28K) and parvalbumin immunocytochemistry in the normal and epileptic human hippocampus. J Comp Neurol. 1991; 308: 381-396.
229. Blümcke I, Beck H, Nitsch R, Eickhoff C, Scheffler B, Celio MR, Schramm J, Elger CE, Wolf HK, Wiestler OD. Preservation of calretinin-immunoreactive neurons in the hippocampus of epilepsy patients with Ammon's horn sclerosis. J Neuropathol Exp Neurol. 1996; 55: 329-341.
230. Blümcke I, Beck H, Suter B, Hoffmann D, Födisch HJ, Wolf HK, Schramm J, Elger CE, Wiestler OD. An increase of hippocampal calretinin-immunoreactive neurons correlates with early febrile seizures in temporal lobe epilepsy. Acta Neuropathol. 1999; 97: 31-39.
231. Kitagawa K, Matsumoto M, Niinobe M, Mikoshiba K, Hata R, Ueda H, Handa N, Fukunaga R, Isaka Y, Kimura K, Kamada T. Microtubule-associated protein 2 as a sensitive marker for cerebral ischemic damage--immunohistochemical investigation of dendritic damage. Neuroscience. 1989; 31: 401-411.
232. Malinak C, Silverstein FS. Hypoxic-ischemic injury acutely disrupts microtubule-associated protein 2 immunostaining in neonatal rat brain. Biol Neonate. 1996; 69: 257-267.
233. Dawson DA, Hallenbeck JM. Acute focal ischemia-induced alterations in MAP2 immunostaining: description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury. J Cereb Blood Flow Metab. 1996; 16: 170-174.
234. Sarnat HB. Hypoxic alterations in neonatal neurons: an acridine orange fluorochromic study of nucleic acids. Brain Dev. 1987; 9: 43-47.
235. Topaloglu H, Sarnat HB. Acridine orange-RNA fluorescence of maturing neurons in the perinatal rat brain. Anat Rec. 1989; 224: 88-93.